interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Relacorilant

Generic competition · all medicines · read 12 November 2026

Is there a generic of Relacorilant, and who makes it?

Relacorilant appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Relacorilant1 dosage-form group in the Orange Book
0generic makers listed
  1. Relacorilant appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Lifyorli (Copackaged). No generic is listed as marketed.

20202025203020352040204501brand 2026data datePatent 10456392 listed to expire 24 May 2033Patent 9273047 listed to expire 24 May 2033Patent 11576907 listed to expire 24 May 2033Patent 8859774 listed to expire 24 May 2033Patent 11925626 listed to expire 18 December 2039Patent 12514849 listed to expire 18 December 2039Patent 11464764 listed to expire 14 April 2040Patent 11285145 listed to expire 26 May 2041Patent 12589094 listed to expire 26 May 2041Patent 12152028 listed to expire 22 December 2041Exclusivity NCE to 25 March 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 25 March 2031Exclusivity NCE Lifyorli (Copackaged)
  • 24 May 2033Patent 10456392
  • 24 May 2033Patent 9273047
  • 24 May 2033Patent 11576907 drug substance
  • 24 May 2033Patent 8859774 drug substance
  • 18 December 2039Patent 11925626 drug product
  • 18 December 2039Patent 12514849 drug product
  • 14 April 2040Patent 11464764 drug product
  • 26 May 2041Patent 11285145

2 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.